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Abstract: Simulations of molecular dynamics (MD) are playing an increasingly important role in
structure-based drug discovery (SBDD). Here we review the use of MD for proteins in aqueous
solvation, organic/aqueous mixed solvents (MDmix) and with small ligands, to the classic SBDD
problems: Binding mode and binding free energy predictions. The simulation of proteins in their
condensed state reveals solvent structures and preferential interaction sites (hot spots) on the protein
surface. The information provided by water and its cosolvents can be used very effectively to
understand protein ligand recognition and to improve the predictive capability of well-established
methods such as molecular docking. The application of MD simulations to the study of the association
of proteins with drug-like compounds is currently only possible for specific cases, as it remains
computationally very expensive and labor intensive. MDmix simulations on the other hand, can be
used systematically to address some of the common tasks in SBDD. With the advent of new tools and
faster computers we expect to see an increase in the application of mixed solvent MD simulations to
a plethora of protein targets to identify new drug candidates.
Keywords: molecular dynamics; cosolvent molecular dynamics; drug design; fragment
screening; docking
1. Introduction
The first revolution in structural biology, in the early 1990’s, increased the available structural
information by 20-fold in a decade, creating a high expectation for computational methods that could
turn this information into drug candidates. A large body of methods emerged, and some drugs owe
their existence—at least in part—to them [1,2]. But it is obvious that the impact of structure-based
drug design (SBDD) has not met these expectations. For instance, out of 66 clinical candidates,
published by the Journal of Medicinal Chemistry in the 2016–2017 period, none originated as a virtual
screening hit [3]. It is a fact that predicting binding affinities (KA = 1/KD = exp(−∆GBIND/RT)) is
terribly difficult, and one of the main compounding factors is the solvent’s effect. Contrary to many
Molecules 2018, 23, 3269; doi:10.3390/molecules23123269 www.mdpi.com/journal/molecules
Molecules 2018, 23, 3269 2 of 14
expectations, designing a good ligand is not a simple matter of finding a molecule that offers a good
shape, or electrostatic and chemical complementarity to its protein target. Binding that occurs in the
presence of solvent and related predictions will always fall short if this is not fully accounted for.
Accurate predictions will unavoidably consider the protein and the ligand embedded in the solvent as
part of a condensed state with a great number of configurational possibilities. Molecular dynamics
(MD) is uniquely suited to simulate such systems by identifying true ensembles that can be related to
macroscopic observables [4]. Here we will review how MD can be used to understand the behavior
of water, the universal biological solvent, in relation to the protein surface, and to accurately predict
its molecular association properties. We will then discuss how MD simulations of proteins in water
and mixed solvents can be used to identify key interactions on their surface, and how these can be
incorporated into computational docking, to identify better drug candidates.
We will start by showing that, far from being empty space, a protein’s binding sites in the
unbound state are occupied mainly by water (but also ions and metabolites) that does not behave
as a homogeneous solvent. Rather, there are well-defined hydration spots and also regions where
water density is much lower than in bulk solvents [5]. This determines binding in ways that were not
initially expected. Solvation also affects the bound state and binding pathways, thus the gold standard
for computational methods is to recapitulate the binding process of a ligand to its target by means of
molecular simulations that consider the solvent explicitly. As the timescale of the binding/unbinding
events has an exponential relationship with molecular size [6], observing binding on a ‘computational
microscope’ [7] is greatly facilitated when the ligand has only a few atoms, particularly if it can be
simulated at high concentrations. In Section 2, we will discuss applications and practical aspects of this
approach (termed MD simulations with mixed solvents, or MDmix for short). The use of simple ligands
as probes to elucidate interaction preferences of protein binding sites has a long history in SBDD.
Except for the crucial difference of including explicit solvation in all the computational procedures,
MDmix-type simulations can trace their roots to Goodford’s GRID [8], Karplus’ MCSS [9] or the more
recent FTmap [10]. All such methods assume that the behavior of the probe is transferable to bigger
molecules. Their documented ability to locate binding hot spots confirm that this is at least partially
true. But binding free energy is clearly a non-additive property, [11,12] thus it becomes necessary to
consider the actual molecules of interest to obtain quantitative predictions. Once considered a dream,
major advances in the field of molecular dynamics (See [13–15] and references therein) have finally
made it possible to directly simulate the binding and unbinding process of actual ligands to their
targets. In Sections 3 and 4, we will review applications with small ligands (fragments) and actual
drugs, respectively. We will conclude by discussing the practical limitations and future perspectives
for the application of these methods in drug discovery.
2. Solvent Structure as a Predictor of Protein-Ligand Interaction Sites
Among the most relevant processes underlying the formation of protein-ligand complexes
is the associated solvent reorganization at the contact surfaces, particularly that of the protein
receptor. Water molecules bound to the ligand binding regions must either be displaced to allow
direct protein-ligand contact [16–19] or be retained, bridging specific protein-ligand interactions,
as is sometimes observed [20–25]. The thermodynamics of this solvent reorganization process is
a key contribution to the complex formation free energy and thus to the ligand binding affinity.
Initial attention was paid to the role of tightly bound or ordered waters, as revealed by X-ray
structures [26], which after displacement by the incoming ligand, were proposed to contribute favorably
to ligand affinity. [21,22]. This observation can be further extended to other proteins even if waters are
not resolved in diffraction experiments due to lack of resolution, by the use of molecular dynamics in
the explicit solvent.
Explicit solvent molecular dynamics allows studying the structure and dynamics of water
molecules, which as a consequence of the shape and charge distribution of protein surfaces,
are distributed inhomogeneously in the solvation shell, giving rise to space regions where the
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probability of finding water molecules is significantly higher (or lower) than that of the bulk solvent,
and where rotational and translational motions of each molecule vary significantly. Wiesner et al.
for example [27], found that confined waters can have residence times in the range of 1 ns to 106
ns, while for the more mobile waters residence times were only 10–50 ps. Further thermodynamic
characterization of these surface waters can be achieved by means of the inhomogeneous fluid solvation
theory (IFST), developed by Lazaridis et. al. [5], through the identification of the so-called water sites
(WS) [28].
Water sites (sometimes also called hydration sites) are defined as confined space regions close
to the protein surface, and internal cavities or packing effects, showing a high probability of finding
a water molecule inside them (water finding probability, WFP). They can be evidenced by the
presence of crystallographic water molecules, or from MD simulations as defined by their position
(whose coordinates correspond to the center of mass of all oxygen atoms, from those water molecules
that visit the site during the simulation timescale), their WFP, and their size (characterized by the R90
values, which describes in Angstrom the radius of the WS that contains a water molecule 90% of the
time). WS are usually identified by applying a clustering algorithm to a collection of snapshots derived
from MD simulations, and despite some special cases, good convergence is achieved in 20–50 ns [29].
In addition to their application as detailed descriptors of the solvent structure, the relevance of
WS determination stems from their capacity to reveal key hydrophilic protein-ligand interaction sites,
such as those established by ligand hydroxyl, carbonyl and carboxylate groups, among others. This is
nicely exemplified by hydrophilic ligands such as carbohydrates, where several groups reported that
the solvent structure in the receptor carbohydrate recognition domain, as revealed by the WS, mimics
the framework of the sugar -OH groups, as shown in Figure 1. Moreover, detailed analysis of WS
properties showed that those WS that are replaced by the incoming ligand-OH group tend to be those
with higher WFP and establishing more interactions with the protein.
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Figure 1. (A) Superposition of Sambucus nigra agglutinin II in complex with Lactose (PDB ID
3CA4) showing how the Water Sites (Orange transparent spheres) mimic the ligand -OH framework.
(B) Escherichia coli AmpC beta-lactamase (PDB ID 1XGI) WS.
More recently, the role WS as predictors of protein-ligand interactions was extended beyond the
sugars, again showing that WS, particularly those with high probe finding probability (PFP), tend to
be replaced by ligand hydrophilic groups that establish key interactions with the protein receptor,
as shown in Figure 1B, for AMPc beta-lactamase.
Having established the tight relationship between WS and protein-ligand interactions, the next
logical move was to apply this knowledge in the context of protein-ligand complex structure
prediction (i.e., docking methods) and determination of ligand binding free energies. However,
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before moving to this topic we will present the use of other solvents as tools for the prediction of
protein-ligand interactions.
3. Mixed Solvents Simulations in Drug Design
While water is the universal biological solvent, organic solvents are ubiquitous in laboratories.
Some exceptional proteins remain active in neat organic solvents and have been explored as catalysts
in industrial applications [30]. More frequently, the buffers used in chemical and structural biology
contain small concentrations of organic solvents. Most proteins preserve their structure and function
in the presence of 1–5% of DMSO and other common organic molecules [31]. This fact led to the
independent observation by NMR and X-ray crystallography that solvents bind preferentially to the
active sites of proteins [32,33]. Systematic studies on proteins crystals showed an increasing number of
solvent interaction sites as the solvent concentration was increased, and some degree of selectivity
for various solvents [34,35]. The most frequently occupied regions coincided with key interaction
sites for the substrates, which agreed with the recently postulated notion of ‘hot spots’, i.e., regions
on the protein surface that provide most of the binding affinity. [36] Interestingly, the same authors
also showed that the computational methods available at the time, GRID [8] and MCSS [9,37] did a
mediocre job at predicting binding sites due to the use of implicit solvation and neglecting entropic
contributions [34,35]. While the possibility of detecting binding sites by crystallography or NMR
with mixed solvents was enticing, the method had limited practical impact because proteins and their
crystals rarely withstand high solvent concentrations. Retrospectively, it may seem surprising that it
took more than 20 years to perform analogous experiments using molecular dynamics, but it wasn’t
until the late 2000’s that MD simulations could routinely explore sufficiently long timescales to ensure
meaningful results. In 2009 the Barril’s lab published the first MD application of mixed solvents.
In this work, the probe solvent was isopropanol to capture in a single molecule, the hydrophobic and
hydrogen bond donor, and acceptor moieties that are common in drug-like molecules. The aim was to
detect binding sites and quantify their potential to bind drug-like molecules [38]. This property,
often referred to as ‘druggability’ (but note the parallelism with the term ‘ligandability’ [39]),
is crucial to predicting the probabilities of successful development of a drug candidate tackling
a particular site [40]. The authors noted that “in addition to a prediction for the (druggability of
the) whole site, one also obtains a map of the interaction preferences”. Independently and almost
simultaneously, the MacKerell’s lab described another mixed solvent approach that focused precisely
on this application [41]. In this case, the solvents used were propane as an aliphatic probe, benzene as
aromatic probe and water itself was used as a polar probe. Probe interaction maps (called FragMaps)
showed an excellent correlation with the binding modes of existing ligands. Since then, a large
number of contributions have emerged. Besides druggability [42–44] and binding site mapping [45,46],
mixed solvents have also been used to predict water displaceability [47,48], to probe protein flexibility
and the detection of more druggable conformations [49], or cryptic pockets [50–52], or used to re-score
docking poses [53,54]. As the diverse implementations and applications of mixed-solvent MD have
been extensively reviewed by Ghanakota and Carlson [55], we will place emphasis on the issue of
convergence, which is essential for correct predictions.
Convergence of a mixed solvents MD is determined by three interrelated aspects that merit
individual discussion: Simulation time, solvent concentration, and protein flexibility.
(1) Simulation time should be sufficient to observe multiple binding and unbinding events.
Naturally, the accuracy of the predictions increases and variability decreases as the number of
observations (N) increases. Ns as low as 5 are sufficient for qualitative applications but must reach
hundreds to be truly quantitative [6]. The other factor determining the total simulation time is the
residence time of the solvent (t1/2 = ln 2/koff; koff∝exp(−∆G /RT) [56]. For barrierless dissociation
(∆GBIND =−∆GTS) t1/2 depends on the binding free energy, which can increase almost linearly with the
number of atoms [57]. Thus, simulation times should increase exponentially with the size of the solvent.
But the pathways leading to and from particular binding sites may be hindered, particularly for large
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ligands, resulting in ∆GBIND << −∆GTS and, in consequence, much larger t1/2. Conventional recipes
suggest running several replicas of 10–40 ns each, for a total timeframe of 50–100 ns. This is sufficient
to ensure qualitative convergence of the published solvents on the surface of the protein. But direct
counting of the number of binding/unbinding events or other forms of measuring convergence should
always be used (Figure 2).
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(2) Solvent concentration increases sampling effectiveness. Not only due to the increase in effective
on-rate (i.e., the number of binding events), but also because multiple binding sites can be sampled
simultaneously. The behavior of the organic solvent should remain ideal (i.e., as in infinite dilution)
to avoid artifacts caused by solvent-solvent interactions in the unbound state (e.g., inhomogeneous
dilution and phase separation). Particular solutions to this problem include the introduction of
repulsive terms between solvent molecules [41], or the use of amphiphilic molecules that are highly
soluble and do not self-aggregate [59]. Additionally, protein dynamics should not be excessively
perturbed by the solvent [60]. Considering that most solvents are denaturants at high concentrations,
concentrations should be kept relatively low (<5%), as the protein could be artificially constrained,
or simulation times could be uch shorter than the denaturation time.
(3) Protein flexibility also deter ines convergence. Ideally, proteins should be allo ed co plete
confor ational freedom, but sampling the configurational space of regular proteins requires excessively
long timeframes. Not only that, but it also complicates interpretation of results, as many hotspots are
conformation-specific and not representative of the whole ensemble [61]. Constraining the mobility of
protein atoms, on the other hand, is a straightforward way of increasing convergence. But this can lead
to the overestimation of some hot spots and missing others. As a compromise, for many applications,
it is useful and correct to use weak restraints that prevent conformational drift but allow sampling of
the local conformational space [61]. Contrarily, if the goal is to induce conformational changes in the
protein, such as the opening of cryptic pockets, simulations should be extended to the µs scale [50–52].
4. Small Ligands and Fragment Screening
Midway between solvent-sized and drug-like molecules, we find the so-called fragments.
Fragment-based drug discovery initial hits are small molecules (roughly 10 to 20 non-hydrogen
atoms) that are then grown and optimized to become standard drugs (30–40 atoms) [62]. Considering
the industrial interest and the small size of these molecules, the use of MD as a screening technique
raises considerable interest. In this approach, each compound in the virtual screening collection would
be considered a probe that would be subjected to long MD simulations in the presence of the target
protein. Probes that bind would then be considered fragment hits.
At present, molecular docking is the tool of choice for virtual fragment screening. Pioneering
work by the Shoichet’s Lab in this area led to the conclusion that although virtual fragment screening
is adequate, with hit rates of 14.5% [63] and correct pose prediction, it mostly finds low specificity
molecules. The effectiveness of this method for screening and de novo design are well documented in
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the literature [64–68]. Docking is particularly well suited for fragment screening since the molecules
used as fragments are small and not very flexible (less than three rotatable bonds). Nevertheless, if the
binding site is not known, it can lead to many false positives. Consensus strategies, like the ones used
in FTMap [10], have been used to identify new binding sites. However, in shallow interfaces, as seen
in many protein-protein interactions (PPI) sites, the lack of proper treatment for the receptor flexibility
can be a drawback for these strategies [69].
MD is an essential tool to include receptor flexibility and therefore to compute the binding free
energy [1,70]. Both Free Energy Perturbation (FEP) and kinetic parameter estimation methods have
been used for fragment discovery, while FEP has been successful for rescoring [71,72] as well as
predicting absolute free energies (but not routinely due to high computational cost) [73–75]. On the
other hand, recent works have focused on the determination of the binding kinetics of small molecules
and fragments from MD simulations [76–79]. Many methods rely on an intelligent design of the
analysis strategy to predict the kinetic binding parameters koff, mainly using Markov state models [80].
Although most of the reports use molecular simulations to characterize the binding kinetics of
known fragments/small molecules [81–83], there are some reports on fragment-based screening
from “first principles” using molecular simulations [84]. The De Fabritiis’ Lab [85] recently presented
a proof of concept of fragment-based screening using MD. They screened a library of 129 fragments
(6 to 16 heavy atoms) using short simulations (100 ns), applying a bias and analyzing the trajectories
with Markov state models (MSMs). Although the authors found promising fragments binding (8 mM)
to the receptor surface (CXCL12), the computational expense is still prohibitive (380,000 GPU hours).
Work at Shaw D.E. Research sets the bar for quantitative prediction for fragment-based drug
discovery [6]. They explored the binding thermodynamics and kinetics of 7 molecules of 4 to 10 heavy
atoms to FKBP protein. After hundreds of direct observations of binding and unbinding events,
they computed the kon, koff and binding affinities. They showed a perfect agreement with FEP
simulations, demonstrating that when convergence is ensured, direct simulation of the binding
equilibrium by molecular dynamics, can be a quantitative tool. Unfortunately, the RMSE of the
computed binding free energy with experimental values was 2.1 kcal/mol, which illustrates the
challenges that still lie ahead.
There is significant scope for cross-fertilization between mixed solvent MD and fragment-based
drug discovery that has not been extensively explored. For instance, fragments often bind to multiple
binding sites on the protein surface [86] which could potentially be identified by cosolvent MD.
Fragments can also induce opening of new cavities (cryptic pockets). Gervasio’s research on an
exciting tool to address this topic, which combines co-solvent MD and advanced sampling (SWISH),
helped to discover cryptic pockets [50,51]. Specifically, simulations on NPC2, p38α, LfrR, and hPNMT
were performed, and due to the combined nature of SWISH and CoSolvent, MD was able to find
all the cryptic pockets. Once in the binding site, the information derived from the cosolvent MD
simulations could potentially be used to predict binding modes and affinities, or to guide the fragment
evolution process. Work in this area has been done by MacKerell’s Group with the SILCS methodology.
They used the information derived from cosolvent MD to derive so-called FragMaps [41]. These grids
were used to rank different ligands and to determine the free energy of binding.
5. Molecular Dynamics Simulations of Drugs or Drug-Like Compounds
Molecular Dynamics simulations could be used to study the free energy of binding of a drug or
a drug-like molecule (30–40 heavy atoms) to a protein. This would require the sampling of several
binding and unbinding events and therefore unbiased MD runs of at least hundreds of microseconds.
Direct observation of drugs binding to their target has been an outstanding achievement of MD
applications. Unbiased simulations have revealed the binding pathways of dasatinib to Src kinase [87]
and alprenolol binding to the β2 adrenergic G protein-coupled receptor [76]. However, due to the
long timescale involved in the dissociation of a drug from its target, direct observation of several
unbinding events is not possible. Massive short unbiased simulations in conjunction with Markok
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State analysis has been used to study benzamidine binding to trypsin [80]. On the other hand,
biased simulations can be used to study the Potential of Mean Force of drug binding. Cavalli published
the first study of its kind, showing that it was possible to discern active from inactive compounds of
the beta-hydroxyacyl-ACP dehydratase of Plasmodium falciparum using steered MD [88]. Since then,
a large variety of biasing potentials have been investigated and applied to the problem [89]. Even so,
the problem remains computationally prohibitive. For instance, the study of a single inhibitor of p38
MAP kinase, that is a fragment of Doramapimod (BIRB 796) and dissociates 4 orders of magnitude
faster than the parent compound, took 6.8 µs of production simulations and a total CPU time of
2.5 million core-hours [90]. In addition, identification of the reaction coordinate is often a trial and
error process that takes considerable human time and is difficult to automatize [89]. Intriguingly the
initial steps of the dissociation may already provide useful information [91], but full reconstruction of
the process and quantitative binding affinity estimates remain a major challenge that is only applicable
to particularly relevant protein-drug pairs.
For higher throughput applications, docking is widely used to predict protein-ligand
interactions and has become extremely useful for virtual screening of huge collections of small
molecules [92–94]. Most popular docking methods show that success rates are highly
system-dependent, with an overall good performance for pose prediction with binding free energy
errors of 2–3 kcal/mol for small drug-like molecules and in the absence of significant receptor
conformational adjustment [95]. However, it is well known that better results can be obtained by
adjusting the docking protocol using previous knowledge for a particular system, such as binding sites
or crucial molecular interactions [96,97].
The term “biased docking” (or “guided docking”) refers to the use of additional, experimental or
in silico, information to influence the outcome of a docking experiment, e.g., the use of chemical
information to favor a certain orientation and conformation of a ligand inside the binding site.
The source of this information can be either the protein target structure or its known ligands.
A protein-derived bias extracts the information directly from the protein surface and its available
molecular interactions and generates a chemically complementary representation of the surface with
more weight on particularly important residues, e.g., those confirmed to be essential for the activity by
point mutations. As we discussed before, the use of probe atoms, functional groups, small molecules
(e.g., mixed solvents) or molecular fragments is another approach to detect important interaction
sites or hotspots without involving actual ligands. In this way, a protein-derived pharmacophore is
obtained and defines energetically favorable binding site locations for docked compounds. A currently
common technique for obtaining these hotspots is to run molecular dynamics simulations with small
probes (see Mixed Solvents section). The hotspots can then be used to adjust the docking protocol, e.g.,
by adding a restriction towards the formation of a given protein-probe interaction. Recently, Arcon
et al. showed that determination of water and/or ethanol sites derived from molecular dynamics
simulations in mixed solvents allowed identification of over 79% of all protein-ligand interactions,
especially those that were most important for the binding [54]. They also stated how this knowledge
could be used to improve docking. On the other hand, a ligand-derived bias extracts the information
from the known ligands for a particular protein target, for example, a particular substructure such
as the core of a congeneric series. Several protein-ligand complex structures are available and the
conserved interactions of the co-crystallized ligands (ligand-derived pharmacophore) can be inferred
and used to improve docking accuracy [97,98].
The improved performance of knowledge-based biased docking is highlighted by the different
options available in the most common docking programs. For example, Glide [99] and GOLD [100]
allow hydrogen bonds and substructure-based constraints, while Glide also permits metal restraints to
enforce coordination geometries. On the other hand, rDock [94] and MOE [101] are able to constrain
generated poses to satisfy pharmacophores, and thus bias the results towards important interactions,
and also perform knowledge-based template guided (or tethered) docking. DOCK6 [102] has a
conformational search option to bias the sampling towards poses in accordance with a defined
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set of known ligand structures. AutoDock [92] and DOCK3 [103] were subjected, by us [29] and
others [104,105], to implementations considering the energy accounted from water displacement
through inhomogeneous solvation theory for guiding the docking. Lopez et al. have proposed a scheme
to add a bias to AutoDock [29] that has been recently implemented for performing biased docking with
AutoDock4 (AutoDock-Bias, in preparation Arcon et al., 2018). The versatile definition of the different
types of biases in AutoDock-Bias accounts for all of the above cases. It allows guided docking towards
pharmacophoric interactions in a straightforward way for hydrogen bond and hydrophobic/aromatic
interactions. Furthermore, it allows researchers to get ideal interaction patterns for a specific protein
structure, thus easily defining interactor locations. In addition, the capability of modifying any specific
energy map and assigning any bias potential strength permits the precise localization of any desired
atom (e.g., metal) or group (e.g., substructure core of a congeneric ligand series or for fragment growth)
in a defined region space relative to the target protein. Finally, the specific energy map modification
may also be used as an anchor for covalent docking studies. Since we addressed the problem of
incorporating single target information, in the present discussion, we omitted potentials used for
docking scoring functions [106–108] generally derived for diverse protein-ligand complexes.
In summary, mixed solvents simulations can lead to the identification of hot spots that can then
be used in biased docking. The bias may affect the conformational search and/or scoring of the
obtained poses.
6. Conclusions and Perspectives
Simulation of molecular dynamics in an explicit solvent are needed for accurate drug design.
As the thermodynamics of the solvent reorganization upon drug binding is a key contribution to the
complex formation free energy and thus to the ligand binding affinity. Therefore, accurate predictions
have to consider the protein and the ligand embedded in the solvent, as part of a condensed state and
have to account for a great number of configurational possibilities. On the other hand, explicit water
MD allows studying the structure and dynamics of water molecules, and therefore the identification
of water sites, that are relevant for their capacity to reveal key hydrophilic protein-ligand interaction
sites. Water provides useful information for drug design, like guiding thermodynamic integration
computations for compound optimization by allowing researchers to predict where it is favorable to
grow the compound by displacing waters [109,110]. Another recent use of water molecules is to design
specific inhibitors between a protein family, like the bromodomain proteins where structural water
position determines drug selectivity [111]. The MD application of mixed solvents allows researchers to
detect binding sites and quantify their potential to bind drug-like molecules. In turn, the identified hot
spots can then be used as a bias in docking simulations to better identify drug candidates.
Mixed solvent MD with a cosolvent of no more than 10 heavy atoms is feasible and as we have
described in this review, can clearly contribute to drug design, but has not yet been fully exploited.
With the advent of new web services and user-friendly software, good algorithms to analyze the
simulations and faster computers, we expect to see an increase in the application of these techniques
to a plethora of protein targets. Docking simulations have not increased accuracy for drug-protein
conformational predictions in the last decade, but most probably will get better in the near future,
with the increased use of knowledge-based algorithms. MDMix will also help to obtain more accurate
binding free energy estimations, but much effort in the community is needed in order to derive new
algorithms that are not only able to estimate the free energy contribution of drug-protein interactions,
but also the free energy of protein and drug desolvation.
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